Menu

Press Releases

Date Summary View
Toggle Summary RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue
Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is ...
View HTML
Toggle Summary RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with MSN Pharmaceuticals
TEL AVIV, Israel and RALEIGH, N.C. , March 25, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc. , AztraZeneca AB and AstraZenca Pharmaceuticals LP ("AZ") and Nektar ...
View HTML
Toggle Summary RedHill Biopharma Announces Compassionate Use Treatment with Opaganib of first COVID-19 Patients in Switzerland
TEL AVIV, Israel and RALEIGH, N.C. , March 22, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has acted on a request to provide opaganib [1] treatment on an outpatient basis under compassionate ...
View HTML
Toggle Summary RedHill Biopharma Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
TEL AVIV, Israel and RALEIGH, N.C. , March 18, 2021 /PRNewswire/ -- Financials : Full year 2020 net revenues of approximately $64 million , with gross profit of approximately $27.5 million Solid cash balance of approximately $100 million as of March 4, 2021   Planned commercial operational ...
View HTML
Toggle Summary RedHill Biopharma to Host Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights Webcast on March 18, 2021
TEL AVIV, Israel and RALEIGH, NC , March 11, 2021 /PRNewswire/ --  RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will report its fourth quarter and full year 2020 financial results and operational highlights on ...
View HTML
Toggle Summary RedHill to Present at Upcoming Conferences in March
TEL AVIV, Israel and RALEIGH, NC , March 5, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present at the following upcoming virtual conferences in March: Sachs Spring Life Sciences Week ( ...
View HTML
Toggle Summary RedHill Biopharma Announces Closing of $35 Million Bought Deal Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C. , March 4, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 4,375,000 American Depositary Shares ...
View HTML
Toggle Summary RedHill Biopharma Increases Previously Announced Bought Deal to $35 Million of American Depositary Shares
TEL AVIV, Israel and RALEIGH, NC , March 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that due to demand, the underwriter has agreed to increase the size of the previously announced public offering ...
View HTML
Toggle Summary RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares
TEL AVIV, Israel and RALEIGH, N.C. , March 1, 2021  /PRNewswire/ -- RedHill Biopharma Ltd .  (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has entered into an underwriting agreement with H.C. ...
View HTML
Toggle Summary RedHill Biopharma Announces Planned Expansion of Opaganib Global Phase 2/3 COVID-19 Study to the U.S.
Following review of data from the U.S. Phase 2 study by the FDA, RedHill plans to expand the global Phase 2/3 study of orally-administered opaganib for severe COVID-19 to the U.S. The study has enrolled over 50% of the targeted 464 patients globally; U.S. ...
View HTML